Aldosterone: Villain or protector?

Hypertension

Volumn 50, Issue 1, 2007, Pages 31-32

  Adler, Gail K ^a   Williams, Gordon H ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b Cardiovascular Imaging Section   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FLUDROCORTISONE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; POTASSIUM; PROTEIN KINASE C;

BLOOD VESSEL INJURY; CARDIOVASCULAR RISK; EDITORIAL; HUMAN; MOLECULAR DYNAMICS; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; VASOCONSTRICTION; VASODILATATION;

ALDOSTERONE; ANIMALS; FOREARM; HUMANS; REGIONAL BLOOD FLOW; VASOCONSTRICTION; VASODILATION;

EID: 34250872343     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.107.090894     Document Type: Editorial

References (9)

1. Martinez DV, Rocha R, Oestreicher E, Ochoa-Maya M, Roubsanthisuk W, Williams GH, Adler GK. Cardiac damage prevention by eplerenone: comparison with low sodium diet or potassium loading. Hypertension. 2002;39:614-618.
2. Arima S, Kohagura K, Xu HL, Sugawara A, Uruno A, Satoh F, Takeuchi K, Ito S. Endothelium-derived nitric oxide modulates vascular action of aldosterone in renal arteriole. Hypertension. 2004;43:352-357.
3. Uhrenholt TR, Schjerning J, Hansen PB, Norregaard R, Jensen BL, Sorensen GL, Skott O. Rapid inhibition of vasoconstriction in renal afferent arterioles by aldosterone. Circ Res. 2003;93:1258-1266.
4. Liu SL, Schmuck S, Chorazcyzewski JZ, Gros R, Feldman RD. Aldosterone regulates vascular reactivity: short-term effects mediated by phosphatidylinositol 3-kinase-dependent nitric oxide synthase activation. Circulation. 2003;108:2400-2406.
5. Nagata D, Takahashi M, Sawai K, Tagami T, Usui T, Shimatsu A, Hirata Y, Naruse M. Molecular mechanism of the inhibitory effect of aldosterone on endothelial nitric oxide synthase activity. Hypertension. 2006;48:165-171.
6. Farquharson CA, Struthers AD. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation. 2000;101:594-597.
7. Farquharson CA, Struthers AD. Aldosterone induces acute endothelial dysfunction in vivo in humans: evidence for an aldosterone-induced vasculopathy. Clin Sci (Lond). 2002;103:425-431.
8. Nietlispach F, Julius B, Schindler R, Bernheim A, Binkert C, Kiowski W, Brunner-La Rocca HP. Influence of acute and chronic mineralocorticoid receptor excess on endothelial function in healthy men. Hypertension. 2007;50:82-88.
9. Schmidt BM, Oehmer S, Delles C, Bratke R, Schneider MP, Klingbeil A, Fleischmann EH, Schmieder RE. Rapid nongenomic effects of aldosterone on human forearm vasculature. Hypertension. 2003;42:156-160.